Current Projects
-
Phase I study of two second generation COVID-19 variant vaccines
The Doherty Institute has been funded through the National Health and Medical Research Council (NHMRC) by the Medical Research Future Fund to conduct a unique Phase I study of two second generation COVID-19 variant vaccines.
Find out more › about Phase I study of two second generation COVID-19 variant vaccines -
Inhaled oligonucleotides to generate a decoy receptor for SARS-CoV-2
This collaborative research project is investigating the potential inhaled treatment for COVID-19 that has a different mechanism than other treatments and vaccines in development.
Find out more › about Inhaled oligonucleotides to generate a decoy receptor for SARS-CoV-2 -
Biologics development program
This program is developing new ‘biologics’ to prevent or treat COVID-19. Biologics are medicines that mimic naturally occurring proteins such as antibodies – immune proteins that fight infection.
Find out more › about Biologics development program -
Clinical trials for SARS-CoV-2 vaccines in Victoria
This platform brings together Australia’s experience and expertise to facilitate the conduct of Phase I and Phase II clinical trials of SARS-CoV-2 vaccine candidates.
Find out more › about Clinical trials for SARS-CoV-2 vaccines in Victoria -
The Doherty Institute COVID-19 vaccine development initiative
Through this initiative, our strategy is to pursue multiple avenues simultaneously, including developing active and passive vaccination platforms.
Find out more › about The Doherty Institute COVID-19 vaccine development initiative -
Host cell kinome project
This project aims to investigate new treatments for COVID-19 by targeting human hosts, rather than the pathogen itself.
Find out more › about Host cell kinome project -
Natural history of immunity and the long-term health impacts of COVID-19 infection
Natural history studies explores the pathogenesis of COVID-19 to inform clinical care and to understand the immune response to the virus.
Find out more › about Natural history of immunity and the long-term health impacts of COVID-19 infection -
Receptor Binding Domain vaccine program
Two vaccine candidates have been developed that represent a next generation vaccine for COVID-19, focusing on the tip of the SARS-CoV-2 virus spike protein - the receptor binding domain (RBD) - and blocking virus attachment and infection.
Find out more › about Receptor Binding Domain vaccine program -
Jack Ma Foundation COVID-19 Vaccine Development Program
This COVID-19 Vaccine Development program was made possible due to a generous donation from the Jack Ma Foundation.
Find out more › about Jack Ma Foundation COVID-19 Vaccine Development Program -
ID predict genomics platform for personalised treatment of COVID-19
The ID Predict platform – led by University of Melbourne researchers at the Doherty Institute in collaboration with computational biologists at the Melbourne School of Engineering and the Water & Eliza Hall Institute, and international genomics company Illumina – will combine cutting-edge human and microbial genomics with multi-disciplinary technology advances to create a platform that is essential to the COVID-19 response, and rapidly deployable for future infectious disease outbreaks.
Find out more › about ID predict genomics platform for personalised treatment of COVID-19